Clinical Research Directory

Compassion-Based Rehabilitation Needs Assessment Following Colorectal Cancer Surgery

This randomized controlled trial evaluated the effect of a compassion-based intervention compared with standard procedure for rehabilitation needs assessment among patients undergoing surgery for colorectal cancer with curative intent. Participants were randomly assigned to either a structured, compassion-supported rehabilitation needs assessment or standard postoperative care. The intervention focused on identifying physical, psychological, and social rehabilitation needs through compassionate communication and facilitating referral to municipal cancer rehabilitation services. The primary outcome was health-related quality of life measured using the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) at three months. Secondary outcomes included anxiety, depression, self-compassion, and participation in cancer rehabilitation.

Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer

Nelmastobart（hSTC810） is a novel humanized monoclonal antibody that fuses on IgG4 and targets a novel immune checkpoint protein, BTN1A1+.This is an phase Ib bridging trial conducted in China to assess the safety, tolerability, and pharmacokinetic characteristics of Nelmastobart in combined with TAS-102 and Bevacizumab in Chinese participants with mCRC, and to verify that the safety results align with those from the Korean STCUBE-003 phase Ib trial. The phase Ib trial will also provide supportive data for conducting a randomized, double-blind, controlled Phase II study in China.